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Inferring antibiotic mechanisms on translation
through static structures has been challenging, as
biological systems are highly dynamic. Dynamic
single-molecule methods are also limited to few
simultaneously measurable parameters. We have
circumvented these limitations with a multifaceted
approach to investigate three structurally distinct
aminoglycosides that bind to the aminoacyl-transfer
RNA site (A site) in the prokaryotic 30S ribosomal
subunit: apramycin, paromomycin, and gentamicin.
Using several single-molecule fluorescence mea-
surements combined with structural and biochem-
ical techniques, we observed distinct changes to
translational dynamics for each aminoglycoside.
While all three drugs effectively inhibit translation
elongation, their actions are structurally and mecha-
nistically distinct. Apramycin does not displace
A1492 and A1493 at the decoding center, as demon-
strated by a solution nuclear magnetic resonance
structure, causing only limited miscoding; instead,
it primarily blocks translocation. Paromomycin and
gentamicin, which displace A1492 and A1493, cause
significant miscoding, block intersubunit rotation,
and inhibit translocation. Our results show the power
of combined dynamics, structural, and biochemical
approaches to elucidate the complex mechanisms
underlying translation and its inhibition.INTRODUCTION
The ribosome is the molecular machine that rapidly and accu-
rately interprets the genetic code on the messenger RNA
(mRNA) to synthesize proteins (Green and Noller, 1997). DuringCelongation, the ribosome repeats the cycle of selecting a transfer
RNA (tRNA) molecule matching the codon in the 30S A site,
incorporating the amino acid from the selected A-site tRNA
into the polypeptide on the P-site tRNA, translocating the
A- and P-site tRNAs to the P and E sites, and stepping precisely
three bases in the 30 direction (Korostelev et al., 2008; Winter-
meyer et al., 2004; Zaher and Green, 2009). To elongate with
an optimal balance of speed and accuracy, the ribosome
employs G protein elongation factors (elongation factor thermo
unstable [EF-Tu] and elongation factor G [EF-G] in bacteria) to
facilitate key steps during the process (Nilsson and Nissen,
2005). Using the energy from guanosine triphosphate (GTP)
hydrolysis, EF-Tu enhances the rate and specificity of tRNA
selection and EF-G catalyzes translocation.
The central role of translation makes the ribosome a rich target
for clinically important small-molecule antibiotics. They employ
diverse strategies to interfere with translation and fall into several
distinct classes, including macrolides, tetracyclines, and amino-
glycosides (Benveniste and Davies, 1973; Bo¨ttger, 2006;
Davies et al., 1965; Perzynski et al., 1979; Woodcock et al.,
1991). Biochemical and structural studies of these antibiotics
have shed light on their mechanism and have, in turn, provided
clues to the molecular workings of the ribosome and its ligands
(Yonath, 2005). Here, we focus on the clinically important amino-
glycosides as a representative group of translational inhibitors.
Aminoglycosides contain a central deoxystreptamine ring with
amino-sugar modifications (4,5 and 4,6 disubstituted deoxy-
streptamine) and include neomycin, paromomycin, gentamicin,
kanamycin, and the fused-ring compound, apramycin. Amino-
glycosides disrupt the fidelity of tRNA selection and block
translocation (Benveniste and Davies, 1973; Davies and Davis,
1968; Davies et al., 1965). Nuclear magnetic resonance (NMR)
and X-ray crystal structures (Fourmy et al., 1998) as well as
biochemical and molecular biological studies (Bo¨ttger et al.,
2001; Powers and Noller, 1991) have revealed the structural
basis for specific aminoglycoside binding to bacterial ribo-
somes. Aminoglycosides bind in the major groove of the 16S
ribosomal RNA (rRNA) decoding site, forming specific contactsell Reports 3, 497–508, February 21, 2013 ª2013 The Authors 497
Figure 1. Aminoglycosides Bind in the 30S
A Site in Helix 44 of the 16S rRNA
(A) The location where aminoglycosides bind to
the bacterial ribosome is shown. The detailed
binding site is shown to the right, with the A-site
tRNA in orange and paromomycin in red. The three
nucleotides in blue are A1408, which is specific
to prokaryotes and conveys the specificity of
aminoglycosides, and A1492/A1493, which are
destacked by aminoglycosides and mimic the
conformation of correct codon-anticodon recog-
nition between the mRNA and the A-site tRNA.
A-site structure with paromomycin is rendered
from PDB 2J00 (Selmer et al., 2006).
(B–D) The structures of the three aminoglycosides
tested. Biochemical experiments have shown that
aminoglycosides induce miscoding and block
translocation. Such effects were also seen in our
single-molecule assays, as shown in Figure S1.with conserved nucleotides G1494 and U1495; ring I of the ami-
noglycosides fits into a prokaryote-specific binding pocket
formed by universally conserved nucleotides A1492 and A1493
and the prokaryotic-specific nucleotide A1408, imparting their
specificity (Bo¨ttger et al., 2001; Recht et al., 1999).
These structural studies suggested a mechanism for amino-
glycoside action (Figure 1A). In the presence of a cognate
codon-anticodon complex, A1492 and A1493 (Moazed and
Noller, 1990) make shape-specific contacts in the minor groove
of the codon-anticodon A-form helix (Fourmy et al., 1998; Ogle
et al., 2001; Yoshizawa et al., 1999). These contacts assist in dis-
tinguishing between correct and incorrect codon-anticodon
pairings, as shown by both structural and kinetic investigations.
In the absence of tRNA or drug, A1492/A1493 are stacked within
an asymmetric internal loop at the base of Helix 44 (h44). Upon
codon-anticodon interaction, A1492/A1493 are displaced from
h44 to make the contacts discussed above. Binding of either
4,5 or 4,6 disubstituted aminoglycosides to the decoding site
mimics this conformational effect, displacing A1492 and A1493
toward the minor groove.
Aminoglycosides alter the kinetics of tRNA accommodation,
supporting these structural predictions (Pape et al., 1998,
2000). Paromomycin significantly reduces the dissociation rate
of near-cognate tRNA and increases the rate of GTPase activa-
tion on EF-Tu by an order of magnitude. These results suggest
that aminoglycosides stabilize near-cognate tRNA binding to
the ribosomewith a 16S rRNA conformation thatmimics cognate
codon-anticodon recognition. While the structural basis of ami-
noglycoside-induced miscoding has become clear, little is
known about how they inhibit the subsequent steps of elonga-
tion. The relative importance of miscoding and inhibiting translo-
cation to the potency of the drugs has not been determined.498 Cell Reports 3, 497–508, February 21, 2013 ª2013 The AuthorsHere, we use a combined dynamics
and structural approach to understand
how distinct aminoglycosides disrupt
translation.
We probed the mechanism of transla-
tional inhibition by an aminoglycosidefrom each of the three distinct structural classes: apramycin
(fused-ring), paromomycin (4,5-linked), and gentamicin (4,6-
linked) (Figures 1B–1D) using single-molecule, structural, and
biochemical approaches. We solved the solution structure of
apramycin bound to the bacterial decoding site by NMR spec-
troscopy, providing a structure to the repertoire of drug-RNA
complexes. We determined the effects of all three drugs on the
dynamics of translation using an array of single-molecule tech-
niques (Aitkenet al., 2010):wemonitored theglobal conformation
of the ribosome during elongation (Aitken and Puglisi, 2010) and
the dynamics of tRNA accommodation by fluorescence reso-
nance energy transfer (FRET) (Blanchard et al., 2004a) and used
zero-mode waveguides (ZMW) to track multiple tRNAs through
several elongation cycles at near physiological concentrations
(Levene et al., 2003; Uemura et al., 2010). We also used bulk
kinetics (Johansson et al., 2011) tomeasure the effects of amino-
glycosides on rates of peptide bond formation and subsequent
translocation. This combination of single-molecule dynamics,
structural, and biochemical techniques reveals the mechanism
of aminoglycoside action at an unparalleled level of detail.
RESULTS
Apramycin, Paromomycin, and Gentamicin Target
Distinct Aspects of the Elongation Cycle
To monitor the global effects of aminoglycosides on elongation,
we used intersubunit FRET between site-specifically labeled
Escherichia coli 30S and 50S subunits (Aitken and Puglisi,
2010; Dorywalska et al., 2005; Marshall et al., 2008) that enable
real-time monitoring of single ribosomes performing multiple
elongation cycles. For each cycle of elongation, the ribosome
rotates the 30S body relative to the 50S and then reverses the
Figure 2. Aminoglycosides Inhibit Translation Elongation at Different Stages
(A) The intersubunit FRET signal involves cycles between a high FRET state where the 30S body of the ribosome is not rotated relative to the 50S subunit and a low
FRET state, where the 30S body is rotated. From previous studies (Aitken and Puglisi, 2010; Marshall et al., 2008), peptide bond formation rotates the 30S body
and causes a transition from high to low FRET. EF-G translocates and counterrotates the 30S body, causing a low to high FRET transition.
(B) An example trace of the intersubunit FRET, where the ribosome translated the entire 6(FK) mRNA. The zoomed panel directly below the diagram in (A)
illustrates the changes in FRET state over one elongation cycle.
(C–F) The lifetimes that each ribosome spends in a conformation state over a given codon are fitted to a single exponential decay function and plotted. From left to
right, the conditions are no aminoglycosides (C, n = 381), 1 mMapramycin (D, n = 429), 1 mMparomomycin (E, n = 264), and 1 mMgentamicin (F, n = 297). Error bars
are SD errors. Different aminoglycosides target different aspects of translation elongation.
See also Figure S2 for lifetimes from additional experiments.rotation, controlled respectively by peptide bond formation
upon tRNA accommodation and translocation. The nonrotated
state is detected by high FRET and the rotated state by a lower
FRET value. The resultant FRET cycles report on the processivityCand dynamics of the ribosome at each codon (Figures 2A and
2B) (Aitken and Puglisi, 2010). All three aminoglycosides signifi-
cantly inhibited elongation efficiency (Figures S1A–S1C; see
Extended Results for details). To probe the mechanistic originsell Reports 3, 497–508, February 21, 2013 ª2013 The Authors 499
of translation inhibition by each aminoglycoside, we leveraged
the ability of this single-molecule FRET approach to detect
codon-specific effects on the dynamics of 30S body rotation
and counterrotation during elongation (Figures 2C–2F and
S2A–S2D) (Aitken and Puglisi, 2010; Marshall et al., 2008).
At 1 mM, apramycin did not measurably affect the lifetime
(4 s) of the high-FRET, or nonrotated state, where the ribosome
selects tRNA and performs peptidyl transfer. In contrast, apra-
mycin lengthened the low FRET, or rotated state, where the ribo-
some waits for EF-G to drive translocation by 2-fold from 5 s
without drugs to 10 s. Increasing apramycin concentration to
10 mM further increased the rotated ribosome lifetime to 3-fold
(15 s) longer than minus drugs, but did not otherwise introduce
any additional effects on elongation. Increasing the EF-G
concentration to 160 nM (from 80 nM, Figures S2E–S2G) partially
rescued the rotated ribosome lifetime (1.6-fold longer than that
minus drugs [8 s]).
At 1 mM paromomycin, the nonrotated state lifetime of the
ribosome at the first codon was increased 2-fold (10 s), but
was unaffected at subsequent codons. Paromomycin also
lengthened the rotated state lifetime to a lesser extent by
1.4-fold (7 s). Increasing the concentration to 10 mM further
lengthened the first nonrotated state lifetime to 3-fold (15 s)
and the rotated state lifetimes to 2-fold of minus drugs (10 s).
Additionally, paromomycin lengthened the rotated state specifi-
cally over the first codon to 4-fold (20 s) from normal. However,
this effect is not observed at 1 mM, suggesting a possible alter-
native binding site (Borovinskaya et al., 2007). Overall, paromo-
mycin displays a more complex set of effects on the elongation
cycle and appears to participate in unique interactions with the
ribosome at the first codon of the mRNA.
At 1 mM, gentamicin had the most severe effects on the non-
rotated state lifetime, lengthening it by 3-fold (15 s) across all
codons, suggesting a mechanism distinct from paromomycin.
However, similar to paromomycin, gentamicin slightly length-
ened the rotated lifetime of the ribosome by 1.6-fold (8 s).
Addition of 10 mM gentamicin led to no further increase in the
nonrotated ribosome lifetime; however, similar to paromomycin,
a secondary effect of a lengthened rotated ribosome lifetime
(to 14 s, a 2.8-fold increase over no drugs) over the first codon
was observed.
In addition to impacting different phases of elongation, the
three aminoglycosides also induce different levels of miscoding,
as described in the Extended Results (Figures S1D–S1F).
Following Real-Time tRNA Transit and Sampling in the
Presence of Aminoglycosides Using ZMW
We next probed the dynamics of aminoglycoside action from the
perspective of tRNA binding by directly tracking in real-time
labeled tRNA binding and transit through the ribosome in zero
mode waveguides (ZMW). The sequence, frequency, and length
of each tRNA signal report on the fidelity of tRNA selection and
on the speed of elongation was based on the dwell time of the
tRNA (Figures 3A and 3B). We have used this approach previ-
ously to track ribosomal compositional dynamics during initia-
tion and elongation (Tsai et al., 2012; Uemura et al., 2010).
In the absence of aminoglycosides, stable binding and transit
of multiple tRNAs on the ribosome were observed as regular500 Cell Reports 3, 497–508, February 21, 2013 ª2013 The Authorspulse cycles of repeating Cy5 followed by Cy2 signals with
regular times between pulses of 1020 s (Figures 3C, 3D, and
S3A–S3C), as observed previously (Uemura et al., 2010). In the
presence of 10 mM apramycin, the time between pulses length-
ened significantly to 3040 s, a nearly 2-fold increase, where the
pulse sequence was still recognizable. Addition of 10 mM paro-
momycin and gentamicin introduces frequent metastable tRNA
binding events of the length of 1  5 s, and the sequences of
those events do not match the codon sequence of the 6(FK)
mRNA used for the experiments (Figure 3E). The abundance of
these short-lived events complicates the identification of binding
events, resulting in accommodation and translocation. See the
Extended Results for the detailed analysis on how the aminogly-
cosides alter tRNA binding behavior (Figures S3D–S3F). This
result is consistent with our intersubunit FRET experiments
that both aminoglycosides severely impact tRNA selection.
Following Real-Time tRNA Dynamics in the Presence
of Aminoglycosides
To delineate the distinct effects of aminoglycosides on tRNA
sampling and selection, we followed FRET between a P-site
fMet-(Cy3)tRNAfMet and an incoming A-site Phe-(Cy5)tRNAPhe
in the presence of antibiotics for an mRNA coding for Met-
Phe-Lys (MFK). The evolution of this FRET signal reports on
the decoding and accommodation of the A-site tRNA as well
as classical to hybrid state fluctuations of the tRNA after
peptide bond formation (Blanchard et al., 2004b; Figures 4 and
S4A–S4C).
Apramycin did not significantly alter the dynamics of tRNA
compared to no drugs. In both cases, FRET events proceeded
to a high (0.8) FRET state within 100 ms of the appearance of
FRET and subsequently fluctuated between high (0.8) and
medium (0.5) FRET, consistent with rapid tRNA selection and
accommodation and peptide bond formation followed by clas-
sical–hybrid dynamics (Blanchard et al., 2004b). However, apra-
mycin increased the overall tRNA FRET lifetime from 10 s in the
absence of drugs to 18 s (Table S1). By blocking of translocation,
apramycin could prevent the eventual dissociation of tRNAfMet
from the E site, preserving FRET.
In contrast, paromomycin significantly altered the behavior of
tRNA on the ribosome and induces many short-lived excursions
(<1 s) from zero FRET to a high (>0.7) FRET level consistent with
accommodated tRNA (Figure S4F). These events dropped the
total FRET lifetime to 1.7 s. While these events are too long to
be tRNA sampling attempts (<30 ms), they are much shorter
than normal tRNA accommodation without drugs. Longer-lived
(15 s) high-FRET events with little to no classical–hybrid state
fluctuations were also observed (Figure S4G), consistent with
single-molecule FRET measurements by Blanchard and
coworkers (Feldman et al., 2010). Together with our ZMW mea-
surements, these data suggest that paromomycin stabilizes
tRNAs when they sample the A site and shifts the classical–
hybrid tRNA conformation equilibrium strongly toward the clas-
sical state. The addition of EF-G enriched longer-lived events,
as described in the Extended Results (Figure S4C).
Gentamicin induced behavior similar to that of paromomycin
in tRNA-tRNA FRET experiments, with short (<1 s) high-FRET
events suggesting that the A-site tRNA has proceeded nearly
Figure 3. Aminoglycosides Alter tRNA Binding Patterns in ZMW tRNA Transit Experiments
(A) Using Phe-(Cy5)tRNAPhe and Lys-(Cy2)tRNALys, tRNA binding behavior and sequence can be observed and tRNA transit through the ribosome can be tracked.
The tRNA signal lifetimes, wait times between tRNA events, and the frequency of the events can be tracked.
(B) An example trace of a tRNA transit experiment without aminoglycosides. The pulse sequence up to the last codon on the 6(FK) mRNA is well-behaved and can
be analyzed codon-by-codon. Over the stop codon, short tRNA events are observed as tRNA sampling in the ribosomal A site. These types of events are greatly
increased in the presence of paromomycin and gentamicin.
(C and D) The waiting times until the next tRNA event over each codon are plotted for the Phe (C) and Lys (D) codons. All error bars are SD. Paromomycin and
gentamicin induce too many short tRNA events with the wrong sequence, which precludes an accurate analysis, as exemplified by the bottom two traces with
10 mM gentamicin.
(E) Many short tRNA binding events, whose sequence does not conform to the repeating Phe-Lys sequence encoded in the 6(FK) mRNA used in this experiment.
(F) A ribosome stalls after the first one or two codons and does not restart until nearing the end of the 300 s observation time in ZMW experiments.
See also Figure S3 for additional analysis of ZMW experiments.to accommodation. A longer-lived high-FRET population with
limited exchanges between the classical and hybrid tRNA
conformations was also observed. These high-FRET eventsCare longer lived than those observed in paromomycin, with a
lifetime approaching the photobleaching time of the FRET pair
(18 s). The overall fraction of the short-lived population is alsoell Reports 3, 497–508, February 21, 2013 ª2013 The Authors 501
Figure 4. Paromomycin and Gentamicin
Disrupts the Selection of the A-Site tRNA
(A) FRET between Cy3-labeled P-site tRNA and
incoming Cy5-labeled A-site tRNA can be used to
track tRNA selection. The evolution of this FRET
signal reports on the dynamic decoding and
accommodation of the A-site tRNA as well as
classical to hybrid fluctuations of the tRNA upon
peptide bond formation (Blanchard et al., 2004b).
(B) An example trace from a tRNA-tRNA FRET
experiment without aminoglycosides on an MFK
mRNA. The traces from tRNA-tRNA FRET exper-
iments are then postsynchronized to have the first
appearance of FRET to be t = 0. The condition for
each panel is listed in the title.
(C) Without drugs on the MFK mRNA (n = 54),
a high FRET (0.75) signal appears and, within
100 ms, the tRNAs begin to fluctuate between the
classical (0.75 FRET) and hybrid (0.5 FRET)
conformations. The FRET signal is present
for >10 s.
(D) Apramycin ( n = 136) does not significantly
affect the tRNA selection process.
(E) Paromomycin ( n = 184) severely alters the
behavior by introducing short (1 s) high-FRET
events and long events (>10 s) with limited clas-
sical/hybrid fluctuations.
(F) Gentamicin ( n = 66) also introduces many sub
1 s events and long events with little classical/
hybrid fluctuations.
See also Figure S4 for additional tRNA-tRNA FRET
experiments and Table S1 for lifetimes of tRNA
events.lower than paromomycin, as shown in the higher relative density
of the long events in the postsynchronized plot and the longer
total tRNA lifetime (6.8 s). These differences suggest a mecha-
nism distinct from paromomycin.
Paromomycin Induces Miscoding
To probe how paromomycin alters tRNA selection fidelity, we
repeated our tRNA-tRNA FRET experiments with an mRNA
encoding Met-Leu-Lys (MLK), in which the Leu codon is CUU,
near-cognate to the Phe UUU codon. Delivery of Phe-(Cy5)
tRNAPhe to immobilized ribosomes initiated with fMet-(Cy3)
tRNAfMet in the P site tested the ability of the ribosome to distin-
guish between cognate and near-cognate tRNA in the A site.
Without drugs and in the presence of apramycin, few detectable
tRNA FRET events were observed. Thus, the ribosome was able
to discriminate against the near-cognate tRNA; mRNA-indepen-
dent binding events did not produce FRET and so were not
detected in these experiments (Blanchard et al., 2004a).
In the presence of paromomycin, we observed many detect-
able tRNA FRET events on the near-cognate CUU codon502 Cell Reports 3, 497–508, February 21, 2013 ª2013 The Authors(Figures S4D and S4E). Similar to the
cognate mRNA experiment, we observed
short excursions to high FRET as well as
longer-lived (15 s) high-FRET events
that showed very limited classical/hybrid
fluctuations. The overall lifetime of tRNAFRET in these experiments (1.41.9 s) was unchanged as
compared to tRNA FRET lifetimes on the cognate MFK mRNA
with paromomycin. In contrast to the MFK cognate experiment,
about 10% of longer-lived events (13 s) were locked in
a medium-FRET state (0.5), consistent with progression to
EF-Tu GTPase activation but not full A-site accommodation
(Lee et al., 2007). Pape and coworkers previously observed
reduced rates of EF-Tu conformational change and tRNA
accommodation after GTPase activation on a near-cognate
codon by the addition of paromomycin (Pape et al., 2000). Over-
all, however, the behavior of tRNA on the cognate MFK and
near-cognate MLK mRNAs was remarkably similar in the pres-
ence of paromomycin. These results further support the view
that paromomycin interferes with the ribosome in distinguishing
between cognate and near-cognate tRNA.
The Apramycin Binding Site on the Ribosome Is Distinct
from that of Other Aminoglycosides
To explore the structural origins of apramycin function, we deter-
mined the NMR solution structure of apramycin in complex with
Figure 5. Apramycin Bound to the A Site
Does Not Destack A1492/A1493
(A) The NMR solution structure with apramycin
shown as lines and the 16S rRNA model shown as
sticks (PDB ID 2M4Q). The three rings of apra-
mycin (plum-colored) are labeled with roman
numerals. The conformation of A1492 and A1493
with paromomycin and gentamicin bound is
shown in light gray for comparison.
(B) The same NMR solution structure as (A) but
viewed from the opposite site of helix 44. The
apramycin-RNA complex structure is colored
explicitly by atom. A1492 and A1493 (highlighted
in light blue) with paromomycin and gentamicin
are shifted with respect to their positions in the
apramycin complex (indicated by the arrows).
The overall structures of the paromomycin and
gentamicin RNA structures are also shown in light
gray for comparison, but apramycin is not shown
for clarity.
See also Figure S5 and Table S2.a 27-nucleotide RNA duplex that mimics the A site of the ribo-
some and the primary binding site of the aminoglycoside antibi-
otics (Recht et al., 1996). TheNMRstructure of paromomycin and
gentamicin C with this model A-site oligonucleotide were previ-
ously published (Fourmy et al., 1996, 1998; Yoshizawa et al.,
1998), and crystal structures with both oligonucleotide and
ribosomal particles are available (Carter et al., 2000; Franc¸ois
et al., 2005). Data on the RNA-apramycin complexwere acquired
on both unlabeled and uniformly 13C, 15N-labeled RNAs (Lukav-
sky et al., 2003; Lukavsky and Puglisi, 2005). A total of 623
nuclear Overhauser effect (NOE) distance restraints, including
32 drug-RNA NOEs, 111 dihedral restraints, and 23 residual
dipolar coupling restraints were used in the structure calcula-
tions. The conformation of the drug-RNA interface was well
defined by the NMR data: the root-mean-square deviation of
the core RNA (U1406-U1410; A1490-U1495) and apramycin for
the final 32 lowest energy structures was 1.21 A˚ (PDB ID 2M4Q).
As with all previous aminoglycoside-RNA complexes, includ-
ing paromomycin and gentamicin C1a, apramycin binding to
the A site was guided by interaction of the 2-deoxystreptamine
ring with G1494 and U1495 (Figures 5 and S5) through hydrogen
bonding interactions with N7 position of G1494 and the O4 posi-
tion of U1495. However, the rigid structure of apramycin led to
a distinct binding mode compared to that in the NMR structures
of paromomycin- and gentamicin-RNA (Fourmy et al., 1996;
Yoshizawa et al., 1998). Apramycin did not penetrate deeply in
to the aminoglycoside binding pocket formed by A1408,
A1492, and A1493, instead making stabilizing interactions with
the phosphate backbone. As a result, apramycin did not stabilize
the extrahelical, or destacked, conformation of A1492 andA1493
observed in the presence of paromomycin and other miscoding
aminoglycosides. Apramycin binding to the oligonucleotide in
solution favors the intrahelical, or stacked, conformation of the
A1408, A1492, and A1493 observed in the structure of the free
A-site oligonucleotide (Recht et al., 1996). Hygromycin B,Canother structurally unique, nonarchetypal antibiotic, binds the
A site but does not cause destacking of A1492 and A1493;
hygromycin B inhibits translocation without causing significant
miscoding (Brodersen et al., 2000; Caban˜as et al., 1978).
Effects of Apramycin, Paromomycin, and Gentamicin on
Peptide Bond Formation Rates
The intersubunit FRET experiments show that paromomycin and
gentamicin inhibit 30S body rotation during elongation. This
could result from delays in peptide bond formation due to disrup-
tion in tRNA selection or steps subsequent to peptide bond
formation. Accordingly, we assayed the effect of the three
aminoglycosides on peptide bond formation kinetics in bulk
experiments, as previously described (Johansson et al., 2011).
The rates of GTP hydrolysis (kGTP) and dipeptide formation
(kpep) for all three drugs remained unchanged compared to no
drugs (Figure 6). As a control, we also measured the rate of
formation of tripeptide (fMet-Phe-Phe) in each case (Figure S6).
The rate of disappearance of f[3H]Met, reflecting the rate of
dipeptide formation, was also the same in each case. The rate
of formation of tripeptides was, however, significantly decreased
by the presence of each one of the drugs, in line with all three
drugs slowing down the ribosome in elongation. These results
suggest that the fraction of drug-bound ribosomes was close
to 100% in the experiments.
DISCUSSION
Aminoglycosides are thought to affect translation by decreasing
the fidelity of tRNA selection and blocking translocation. We em-
ployed a battery of complementary single-molecule methods,
supported by structural and biochemical techniques, to form
a coherent picture of the mechanism of action for three struc-
turally distinct antibiotics: paromomycin, gentamicin C, and
apramycin (Figure 7).ell Reports 3, 497–508, February 21, 2013 ª2013 The Authors 503
Figure 6. No Effect of Aminoglycosides on
Peptide Bond Formation Rates
The extent of hydrolysis of EF-Tu-bound GTP (A)
and dipeptide formation (B) were monitored over
time upon mixing of Phe-tRNAPhe:EF-Tu:GTP
ternary complex with preinitiated 70S ribosomes
in the presence or absence of each type of drug,
as indicated in the figure. The rate of GTP hydro-
lysis, kGTP, (C) and the rate of tRNA accommoda-
tion/peptidyl transfer, kpep, (D) obtained from the
inverse of the difference between the dipeptide
formation time and GTP hydrolysis time were
estimated for each case. Error bars in (C) and (D)
represent SD as calculated from the fitting
procedure averaged over two separate experi-
ments (Johansson et al., 2011).
See also Figure S6.Apramycin Slows Translation via One Primary Inhibition
Mechanism
Apramycin has the clearest but themost atypical mode of action.
The NMR solution structure of the apramycin-ribosomal RNA
complex suggested a distinct structural mechanism for inhibition
of translocation. The apramycin structure shows that the drug
binds in the major groove of the 16S rRNA decoding site similar
to other aminoglycosides. However, the drug does not induce
the destacked conformation of A1492/A1493, as observed
during correct codon-anticodon pairing. This differs with X-ray
crystal structures showing A1492/A1493 destacked for all ami-
noglycosides (see Extended Discussion). However, the recent
crystal structure of apramycin bound to the 30S subunit-tRNA-
mRNA complex suggests that the drug would block unstacking
of A1492 (Matt et al., 2012), consistent with this interpretation.
The bias for a stacked conformation of A1492/A1493 in the pres-
ence of apramycin is supported by lower level of miscoding
observed here and by others (Matt et al., 2012). This bias could
additionally reduce the impact of apramycin on elongation
dynamics over cognate codons prior to 30S body rotation, as
evidenced by the normal nonrotated lifetime in intersubunit
FRET, behavior in tRNA-tRNA FRET that is indistinguishable
from no drugs, low tRNA sampling frequency in the ZMW (see
Extended Discussion), and lack of effect on cognate kpep.
Apramycin mainly blocks translocation; it significantly
lengthens the rotated state lifetime, where the 70S complex is
waiting for EF-G in order to translocate. While a previous
single-molecule work (Feldman et al., 2010) has correlated inhi-
bition in translocation to perturbations in tRNA conformational
dynamics, apramycin breaks this trend, as it strongly inhibits
translocation without inducing any noticeable increase in the504 Cell Reports 3, 497–508, February 21, 2013 ª2013 The Authorsoccupancy of the classical tRNA confor-
mational state in our tRNA-tRNA FRET
experiment. Apramycin may instead
lock the A site in an unfavorable confor-
mation for EF-G, effectively increasing
the energy barrier that EF-G must over-
come to translocate. Similar effects
have been observed for the translocation
inhibitor spectinomycin, which binds the30S subunit (Aitken and Puglisi, 2010). Apramycin inhibits the
rate of elongation for about ten codons into the message, yet it
gradually wears off such that the rotated-state lifetime has
mostly recovered by the end of our 6(FK) mRNA. This suggests
that the early phase of translation is more vulnerable to antibiotic
action.
Paromomycin and Gentamicin Exhibit More Complex
Modes of Action
Paromomycin disrupts multiple aspects of elongation, consis-
tent with the conformational changes observed by structural
methods. By favoring the destacked A1492/A1493 conformation
(Fourmy et al., 1998), it causes severe miscoding in our stop
codon readthrough assay. From tRNA-tRNA FRET experiments
with a near-cognate codon (MLK) mRNA, the many observable
events suggest that paromomycin slows the dissociation of an
incorrect tRNA from the A site, consistent with prior kinetic
measurements (Pape et al., 2000). Strikingly, paromomycin still
retained half of its miscoding effect in our miscoding assay,
where only the noncognate tRNAPhe (to the stop codon) was
present. As the total tRNA concentration in the experiment is
halved, this result suggests tentatively that destacking of
A1492/A1493 can induce miscoding with any tRNA available.
The incorrect pulse sequence in ZMWexperiments with paromo-
mycin further demonstrates that the ribosome has lost its ability
to distinguish correct codon-anticodon interactions.
The effects of paromomycin on elongation appear during both
global conformational states of the ribosome and sometimes in
a codon-specific manner. The frequent short tRNA FRET events
indicate that the ribosome goes through many futile cycles
where it accepts a tRNA into the A site, bypassing initial
Figure 7. Aminoglycosides Disrupt Various Steps of Elongation
(A) In a normal elongation cycle, ribosome rotation occurs quickly after peptide
bond formation between the A- and P-site tRNAs, allowing the tRNAs to
fluctuate between the classical and hybrid states. EF-G then translocates and
counterrotates the ribosome, moving the tRNAs into the P and E sites to reset
the ribosome for another round of elongation.
(B) Apramycin does not hinder the rotation of the ribosome upon peptide bond
formation; however, it blocks the translocation step where EF-G is involved.
This mode of action differs from other members of the aminoglycoside family.
(C) Paromomycin and gentamicin display a more complex set of effects on
elongation, slowing down both the rotation of the ribosome and translocation
as well as inducing severe miscoding. With the ribosome stalled, the A-site
tRNA could eventually dissociate with the short peptide chain due to a finite
off-rate for tRNAs on the ribosome, leading to a stalled ribosome.selection, but eventually rejects it. The high tRNA FRET level
suggests that the A-site tRNA has proceeded beyond GTP
hydrolysis by EF-Tu. Normal bulk peptide bond formation rate
suggests that some tRNAs proceed as far as transferring the
peptide chain from the P-site tRNA to the A-site tRNA. Combined
with the increased nonrotated state lifetime in intersubunit FRET
experiments, this suggests that paromomycin significantly
increases the energy barrier to 30S body rotation, decoupling it
from peptide bond formation. If a ribosome stalls early in elonga-
tionwith a short peptide chain, it could risk losing the A-site tRNA
by dissociation. Such ribosomes are left with a deacylated P-siteCtRNA and are unable to translocate normally, even when
a correct tRNA binds in the A site, as indicated by the frequent
short-lived binding events observed in the ZMW for stalled
traces. Eventually, the ribosome might translocate spontane-
ously with an acylated A-site tRNA bound and reset itself with
an amino acid on the P-site tRNA; however, accumulation of
prematurely released peptidyl-tRNA could be toxic. Consistent
with that hypothesis, some traces that halted at the first codon
in both intersubunit FRET and ZMW experiments subsequently
resumed accommodating tRNAs (Figure 3F). These severely
malfunctioning ribosomes can also become candidates for
termination by release factors in vivo (Dunkle and Cate, 2010),
aborting translation after significant energy expenditure.
Paromomycin additionally prolongs the rotated state in
general; however, this effect is weaker than apramycin. Paromo-
mycin limits the classical/hybrid tRNA FRET fluctuations,
favoring the classical state, which is not conducive for transloca-
tion, consistent with observations of Feldman et al. (2010). Alter-
natively, the stabilized, destacked conformation of A1492 and
A1493 may conflict with EF-G function to reset the ribosome
(Taylor et al., 2007). For both mechanisms, paromomycin effec-
tively increases the energy barrier for the ribosome to translo-
cate. Additionally, paromomycin can significantly lengthen the
rotated lifetime of the first codon, but this is only observed at
10 mM paromomycin concentration. This suggests the presence
of a secondary binding site; however, the mechanism for this
codon-specific effect is not clear.
Gentamicin C, which also promotes the destacked A1492/
A1493 conformation upon binding, induces miscoding as paro-
momycin. Gentamicin causes a similar increase in rotated
ribosome lifetimes as well as locks the tRNAs into the classical
conformation in tRNA-tRNA FRET experiments (Feldman et al.,
2010). Additionally, gentamicin induces short-lived tRNA-
binding events, like paromomycin in ZMW experiments. Unlike
paromomycin, gentamicin increases the energy barrier to ribo-
some rotation across all codons, resulting inmore severe disrup-
tions than paromomycin. Gentamicin is 4,6 linked, and its ring III
element contacts G1405 in the decoding site (Yoshizawa et al.,
1998), whereas the additional ring contacts in 4,5 disubstituted
aminoglycosides occur to the helical stem closed by C1409-
G1491 (Fourmy et al., 1996). These different contacts and their
effects on local and global ribosomal dynamics may explain
the different mechanistic observations. Alternatively, secondary
binding sites may also contribute. Intriguingly, gentamicin has
the strongest inhibitory effect and is the most important of the
three drugs in clinical applications.
Dissecting the Complex Effects of Aminoglycosides
from Multiple Perspectives
By employing complementary single-molecule techniques,
buttressed by structure and biochemical assays, our results
provide a comprehensive understanding of aminoglycoside
mechanisms. Their mode of action is far from simple and
involves significant modifications to the delicate energy land-
scape of elongation. Aminoglycosides have distinct profiles of
elongation inhibition, and their structural diversity indeed trans-
lates into a diversity of mechanisms. While aminoglycosides
are thought to be effective by inducing miscoding and hinderingell Reports 3, 497–508, February 21, 2013 ª2013 The Authors 505
translocation, we have observed significant differences in the
level of miscoding and effects on steps not directly linked to
translocation, which for paromomycin and gentamicin were
stronger than their effects on translocation. Despite the
complexity of their mechanism, a common theme emerges
where they significantly increase energy barriers for the ribo-
some subunits to rotate and to translocate. As the 1.5- to
4-fold inhibitions over each codon to various steps of the elonga-
tion cycle accumulate across multiple codons, these drugs can
effectively stall the ribosome and cause severe disruptions to
elongation. In fact, even with our 12-codon model mRNA, we
already see a dramatic decrease in the number of codons trans-
lated during our observation timeframe. These observations
agree with the original discussions of Kurland (Kurland, 1987)
and others that aminoglycosides are bacteriocidal because of
their inhibition of elongation efficiency, not miscoding. How the
local conformational changes caused by aminoglycoside
binding to the 30S decoding site affect the global behavior of
the ribosome and how miscoding aminoglycosides modify the
balance of tRNA selection fidelity versus efficiency remain
open questions (Johansson et al., 2012).EXPERIMENTAL PROCEDURES
Single-Molecule Reagents and Buffers
Fluorescently labeled 30S (Cy3 or Cy3B) and 50S (Cy5) subunits, wild-type
30S and 50S subunits, translation factors, S1, mRNA, fluorescently labeled
tRNA (fMet-[Cy3]tRNAfMet, Phe-[Cy5]tRNAPhe, and Lys-[Cy2]tRNALys), and
unlabeled tRNA (fMet-tRNAfMet, Phe-tRNAPhe, and Lys-tRNALys) were pre-
pared as previously described (Blanchard et al., 2004b; Dorywalska et al.,
2005; Marshall et al., 2008). All experiments were conducted in a Tris-based
polymix buffer consisting of 50 mM Tris-acetate (pH 7.5), 100 mM potassium
chloride, 5 mM ammonium acetate, 0.5 mM calcium acetate, 5 mM magne-
sium acetate, 0.5 mM EDTA, 5 mM putrescine-HCl, and 1 mM spermidine.
All experiments also contained 4 mM GTP. The aminoglycosides used in this
study were purchased from Sigma as dry powders and dissolved in water to
make stock solutions.
The 50 biotinylated mRNAs for the intersubunit FRET and ZMW experiments
contained the 50 UTR and Shine-Dalgarno sequence of T4 gene 32 followed by
either three Phe (UUU) codons (3F) or six alternating Phe (UUC) and Lys (AAA)
codons (6(FK)). Both 6(FK) and 3F have a stop codon after the end of the
message followed by an additional 4 Phe (UUU) codons (Aitken and Puglisi,
2010). The mRNAs for tRNA-tRNA FRET experiments either contain the full
T4 gene 32 sequence up to the 7th translated codon (MFK) or have the second
translated codon changed from Phe (UUU) to a Leu (CUU) (MLK). All mRNAs
were chemically synthesized by Dharmacon.
NMR Solution Structure of Apramycin in Complex with A-Site
Oligonucleotide Mimic
Near-complete assignment of the proton resonances from the apramycin-
RNA complex was accomplished using standard multidimensional, homonu-
clear, and heteronuclear experiments with unlabeled RNA, and uniformly
13C, 15N-labeled RNA samples (Lukavsky et al., 2003; Lukavsky and Puglisi,
2005). A total of 612 nuclear Overhauser effect (NOE) distance restrains
were determined from two-dimensional (2D) and three-dimensional (3D)
NOE spectroscopy (NOESY) experiments, of which 32 were intermolecular
RNA-apramycin distance restraints. Distance restraints were categorized
based on peak intensity into four groups with the following interproton
distances: strong (1.8–3.5 A˚), medium (2.0–4.5 A˚), weak (2.2–6.0 A˚), and very
weak (3.0–7.0 A˚). Dihedral restrains, b, ε, c, were determined from 3D HCP,
3D heteronuclear multiple quantum coherence (HMQC) total correlation spec-
troscopy (TOCSY), and 2DNOESY experiments, respectively. Residual dipolar
coupling restraints from aromatic N–H andC–Hbond vectors were determined506 Cell Reports 3, 497–508, February 21, 2013 ª2013 The Authorsby comparing J-coupling constants collected from 2D 13C/15N transverse
relaxation optimized spectroscopy (TROSY) spectra in the presence and
absence of pf1 bacteriophage. Residual dipolar couplings (RDCs) were
determined according to the following formula:
1DXH =
1JXHðwith phageÞ  1JXHðwithout phageÞ;
where 1DXH is the dipolar coupling and
1JXH is the one bond scalar coupling for
X = 13C or 15N. The magnitude of C–H RDCs were normalized to those
collected for N–H bonds. A breakdown of the restraints used to determine
the structure of the apramycin-RNA complex is shown in Table S2. Structures
were calculated according to a previously published multistep simulated
annealing protocol using only distance and dihedral restraints during the first
stage implemented in XPLOR (Wimberly et al., 1993). RDCs were incorporated
into the structure determination during a second stage, as described previ-
ously in CNS (Lynch et al., 2003).
Intersubunit FRET Experiments
We mixed 0.25 mM Cy3B-30S, preincubated with stoichiometric S1, 1 mM IF2,
1 mM fMet-tRNAfMet, 1 mM 50 biotinylated mRNA, and 4 mM GTP to form 30S
preinitiation complexes (PICs) in the Tris-based polymix buffer described
above to form 30S PICs (Dorywalska et al., 2005). The PIC mixture was
incubated at 37C for 5 min.
Before immobilizing the 30S PICs on a slide surface, we diluted the mixture
with the Tris-based polymix buffer with 1 mM IF2 and 4mMGTP. The PICswere
then immobilized on the surface of a biotin-polyethylene glycol (PEG)-derivat-
ized quartz slide via biotin-neutravidin interactions.We then washed excessive
unbound material with the Tris-based polymix buffer containing 1 mM IF2,
4 mM GTP, 1 mM Trolox (to stabilize Cy5 photophysics), and an oxygen-
scavenging system (2.5 mM 3,4-dihydroxybenzoic acid and 250 nM protoca-
techuate deoxygenase; Aitken et al., 2008). We delivered 50 nM Cy5-50S,
1 mM IF2, 80 or 160 nM EF-G, 80 nM ternary complexes, and aminoglycosides
(where applicable at the indicated concentration) in the Tris-based polymix
buffer using a controlled syringe pump to initiate translation. Phe-tRNAPhe
and Lys-tRNALys ternary complexes with EF-Tu(GTP) were formed immedi-
ately before delivery, as previously described (Marshall et al., 2008).
ZMW Experiments
The preparation for ZMW experiments was the same as intersubunit experi-
ments with the following exceptions. The first incubation mixture contains
0.25 mM unlabeled wild-type 30S, 0.25 mM wild-type 50S, 1 mM fMet-(Cy3)
tRNAfMet, 1 mM 50 biotinylated mRNA, and 4 mM GTP to form 70S initiation
complexes (ICs). The 70S ICs are then immobilized using the same procedure
as in intersubunit FRET experiments. The delivery mixture contained 1 mM IF2,
200 nM EF-G, 200 nM Phe-(Cy5)tRNAPhe ternary complexes, 200 nM Lys-
(Cy2)tRNALys ternary complexes, and 10 mM paromomycin, apramycin, or
gentamicin, comparable to intersubunit FRET conditions.
tRNA-tRNA FRET Experiments
The preparation for tRNA-tRNA FRET experiments was the same as ZMW
experiments with the following exception. The delivery mixture contains
1 mM IF2, 500 nM EF-G (where applicable), 25 nM Phe-(Cy5)tRNAPhe ternary
complexes, and 10 mM aminoglycosides (where applicable).
Bulk Kinetic Experiments
Bulk kinetic experiments were performed at 20C and pH 7.5 in polymix buffer
(95 mM KCl, 5 mM NH4Cl, 5 mM Mg(OAc)2, 0.5 mM CaCl2, 8 mM putrescine,
1 mM spermidine, 5 mM potassium phosphate, and 1 mM DTE) comple-
mented with an energy supply and regeneration system consisting of 2 mM
(ATP + GTP), 10 mM phosphoenolpyruvate, pyruvate kinase, and myokinase
(Johansson et al., 2011). In the experiments for simultaneous monitoring of
dipeptide formation and GTP hydrolysis, preinitiated 70S ribosomal com-
plexes, carrying f[3H]Met-tRNAfMet in P site and displaying the Phe codon
UUC in A site, were rapidly mixed with preformed Phe-tRNAPhe:EF-Tu:[3H]
GTP ternary complex in a quench-flow instrument (RQF-3, KinTek Corp.) to
a final concentration of 200 nM. The reactions were quenched with formic
acid at different incubation times and the fractions of products, [3H]GDP/([3H]
GDP + [3H]GTP) and f[3H]Met-Phe/(f[3H]Met-Phe + f[3H]Met), were estimated
by high-performance liquid chromatography (HPLC) as described (Johansson
et al., 2011). The rates of GTP hydrolysis and dipeptide formation were
measured in the presence (10 mM) and absence of each drug. The rate of
GTP hydrolysis, kGTP, including the association of ternary complex to the ribo-
some, and the rate of tRNA accommodation/peptidyl transfer, kpep, obtained
from the inverse of the difference between the dipeptide formation time and
GTP hydrolysis time (Johansson et al., 2011) were estimated in drug absence
and in the presence of each one of the drugs. Tripeptide formation was per-
formed by rapid mixing and quenching of mixtures similar to those used for
dipeptide bond formation, but with EF-G and EF-Ts added to the ternary
complex mix and use of unlabeled rather than labeled GTP.
For further details, please refer to Extended Experimental Procedures.
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